CytomX Therapeutics, Inc.·4

Dec 12, 2:35 PM ET

Kavanaugh William Michael 4

4 · CytomX Therapeutics, Inc. · Filed Dec 12, 2017

Insider Transaction Report

Form 4
Period: 2017-12-08
Kavanaugh William Michael
CSO, Head Res.&Non-Clin. Dev.
Transactions
  • Exercise/Conversion

    Common Stock

    2017-12-08$1.57/sh+5,130$8,07919,047 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2017-12-085,130240,912 total
    Exercise: $1.57Exp: 2025-02-08Common Stock (5,130 underlying)
Footnotes (1)
  • [F1]This option vests 25% on January 9, 2016, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, with each additional installment vesting on the last day of the month.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4